Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00290628 · ClinicalTrials.gov registry record · NA
Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer
A NA study, sponsored by Masonic Cancer Center, University of Minnesota.
- Terminated
- Registry status
- NA
- Development phase
- 43
- Enrollment target
NCT00290628: Clinical Trial NA study, sponsored by Masonic Cancer Center, University of Minnesota.
NCT00290628 is a NA study that was terminated before completion, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 43 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00290628, a NA study, was terminated before completion, sponsored by Masonic Cancer Center, University of Minnesota.
- TERMINATED
- Registry status
- NA
- Development phase
- 43 participants
- Enrollment target
Study Summary
RATIONALE: Giving chemotherapy and total-body irradiation before a donor umbilical cord blood transplant helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system from rejecting the donor's stem cells. When the stem cells from a related or unrelated donor, that do not exactly match the patient's blood, are infused into the patient they may help the patient's bone marrow to make stem cells, red blood cells, white blood cells, and platelets. PURPOSE: This clinical trial is studying how well donor umbilical cord blood transplant works in treating patients with hematologic cancer.
Interventions
- DRUG cyclophosphamide
- DRUG filgrastim
- DRUG busulfan
- DRUG cyclosporine
- DRUG anti-thymocyte globulin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 1999-10 |
| Est. Completion | 2007-04 |
| Phase | NA |
Why NCT00290628 stopped before completion
NCT00290628 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 43 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00290628 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00290628 about?
NCT00290628 is a clinical study titled "Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer". RATIONALE: Giving chemotherapy and total-body irradiation before a donor umbilical cord blood transplant helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system from rejecting the donor's stem cells. When the stem cells from a related or unrelated donor, that do...
What is the current status of trial NCT00290628?
This trial is currently terminated. It is a NA study. The enrollment target is 43 participants. The study started on 1999-10. Estimated completion is 2007-04.
What interventions are being tested in trial NCT00290628?
The interventions under investigation include: cyclophosphamide (DRUG), filgrastim (DRUG), busulfan (DRUG), cyclosporine (DRUG), anti-thymocyte globulin (DRUG).
Who is sponsoring clinical trial NCT00290628?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00290628's enrollment target sits among peer trials
43 1435th of 2000 higher than 565 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03726359 · 43 participants · Phase 1
Phase I Study of Fractionated Stereotactic Radiation Therapy
- NCT03850418 · 43 participants · Phase 2
Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
- NCT04144023 · 43 participants · Phase 1
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
- NCT04176718 · 43 participants · Phase 2
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia